Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

NCT00980447 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

UMN Pharma Inc.